Prof Jennifer Kuk, York University, Toronto says that the artificial sweeteners may help in cutting calories and weight loss. But sugar substitutes such as artificial sweeteners will cause changes to gut bacteria.
The changes in the gut bacteria can cause glucose intolerance and increase the risk of type 2 diabetes (T2D). The study has found that artificial sweeteners may not be helpful to the health of our body. Our body cannot digest the artificial sweeteners. They may harm our health.
The study has found a higher body mass index (BMI) in people consuming artificial sweeteners. The study was published in the Applied Physiology, Nutrition and Metabolism.
iGlarLixi is an investigational drug for the treatment of type 2 diabetes (T2D) from Sanofi. iGlarLixi is a combination of.
FDA advisory committee has approved this drug. The approval was issued by the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). The advisory panel says the Food and Drug Administration (FDA) should approve iGlarLixi.
Gangrene will be developed in those people who are affected with type 2 diabetes (T2D). The risk of gangrene often leads to an amputation. Nearly 7,000 amputations happen in the United Kingdom.
Diabetes damages every organ of the body. High glucose levels in the blood can damage the small arteries and restrict the flow of blood. Our antibodies cannot attack the infection due to the poor circulation of the blood leading to amputation of the leg, foot or toes.
Even if a surgeon performs a bypass surgery to prevent the poor blood circulation by inserting a stent in the artery, the blockage in the artery may happen again.
The National Institute for Health and Care Excellence (NICE) says all children with diabetes should check the following tests annually.
But almost 75 percent of the children in England and Wales were not undergoing the annual health checkup. But the experts say that the average blood glucose level (HbA1C) in children with diabetes fell for the 5thyear. HbA1C is a marker that measures overall diabetes control.
The patients have missed the following preventive health checkups.
Prof Ann Simpson and her team have developed the Melligen cells. They are genetically engineered to produce, store and release insulin as per the requirement of our body for the treatment of type 1 diabetes (T1D).
The Melligen cells will be transplanted into humans by using "Cell-in-a-Box" technology as our immune system normally finds and destroys foreign cells. The team secured patents for the Melligen cells from US Patent and Trademark Office. Now, the group is working with the PharmaCyte Biotech Inc. to commercialize the "Melligen" cells.
An accurate prediction system for the remission of diabetes after bariatric surgery was designed. The tool is inexpensive and easy to use. Researchers used the DiaRem score to calculate the score of the patients. The tool is based on the age of the patient, dependence on insulin, diabetes drugs being used and HbA1c levels of the patient.
Author of the study was Dr. Annemarie Hirsch Ph.D., MPH Geisinger Institute, Pennsylvania. The study was published in the JAMA Surgery. The study was funded by the Geisinger Clinic.
Wisit Cheungpasitporn, MD, Mayo Clinic, Rochester, have conducted a meta-analysis from the data of 12 separate studies. The study has found a risk of diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.